Clinical Trials

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06364410 2026-04-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Recruiting

48 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT07012031 2026-04-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07137416 2026-04-13

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04482309 2026-04-09

DPT02

477 enrolled 2 FDA

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

840 enrolled

HER2-positive Gastric Cancer

NCT07198724 2026-04-09

ERADICATE

Phase 1/2 Recruiting

65 enrolled

Breast Neoplasms

NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

64 enrolled

Gastric Adenocarcinoma

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Phase 3 Recruiting

250 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT06989112 2026-04-08

DE-01

Phase 3 Recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05744375 2026-04-02

TRANSCENDER

Phase 2 Terminated

2 enrolled 10 charts

Breast Neoplasms

NCT06486883 2026-04-02

PONTIAC

200 enrolled

Advanced Breast Cancer

NCT05480384 2026-04-01

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

1 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07371585 2026-03-27

TOP-REAL

300 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

150 enrolled

Unresectable Locally Recurrent Breast Cancer

NCT04539938 2026-03-23

HER2CLIMB-04

Phase 2 Completed

70 enrolled 23 charts

Breast Neoplasms

NCT04639219 2026-03-23

DPT01